179 related articles for article (PubMed ID: 6351368)
1. The effect of cyclosporine on early graft function in human renal transplantation.
Flechner SM; Payne WD; Van Buren C; Kerman R; Kahan BD
Transplantation; 1983 Sep; 36(3):268-72. PubMed ID: 6351368
[TBL] [Abstract][Full Text] [Related]
2. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
Lewis RM; Johnson PC; Golden D; Van Buren CT; Kerman RH; Kahan BD
Transplantation; 1988 Feb; 45(2):353-9. PubMed ID: 2830686
[TBL] [Abstract][Full Text] [Related]
3. Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts.
Tilney NL; Chang A; Milford EL; Whitley WD; Lazarus JM; Ramos EL; Strom TB; Carpenter CB; Kirkman RL
Ann Surg; 1991 Jul; 214(1):42-9. PubMed ID: 2064470
[TBL] [Abstract][Full Text] [Related]
4. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
Sutherland DE; Fryd DS; Strand MH; Canafax DM; Ascher NL; Payne WD; Simmons RL; Najarian JS
Am J Kidney Dis; 1985 Jun; 5(6):318-27. PubMed ID: 3893106
[TBL] [Abstract][Full Text] [Related]
5. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United Network for Organ Sharing.
Sarwal MM; Cecka JM; Millan MT; Salvatierra O
Transplantation; 2000 Dec; 70(12):1728-36. PubMed ID: 11152105
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
Schulak JA; Mayes JT; Moritz CE; Hricik DE
Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
[TBL] [Abstract][Full Text] [Related]
7. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine.
Canafax DM; Torres A; Fryd DS; Heil JE; Strand MH; Ascher NL; Payne WD; Sutherland DE; Simmons RL; Najarian JS
Transplantation; 1986 Feb; 41(2):177-81. PubMed ID: 3511581
[TBL] [Abstract][Full Text] [Related]
8. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
[TBL] [Abstract][Full Text] [Related]
9. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity.
Reinsmoen NL; Matas AJ
Transplantation; 1993 May; 55(5):1017-23. PubMed ID: 7684534
[TBL] [Abstract][Full Text] [Related]
10. Preservation.
Ito T; Iwaki Y; Terasaki PI
Clin Transpl; 1986; ():299-310. PubMed ID: 3154422
[TBL] [Abstract][Full Text] [Related]
11. The role of cold ischemia in a provincial organ-sharing program in the cyclosporine era.
Jordan ML; Aprile MA; Cardella CJ
Transplantation; 1990 Feb; 49(2):367-73. PubMed ID: 2305466
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing triple-drug and double-drug therapy in renal transplantation.
Ponticelli C; Tarantino A; Montagnino G; Aroldi A; Banfi G; De Vecchi A; Zubani R; Berardinelli L; Vegeto A
Transplantation; 1988 May; 45(5):913-8. PubMed ID: 3285536
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome.
Kerman RH; Susskind B; Buyse I; Pryzbylowski P; Ruth J; Warnell S; Gruber SA; Katz S; Van Buren CT; Kahan BD
Transplantation; 1999 Dec; 68(12):1855-8. PubMed ID: 10628764
[TBL] [Abstract][Full Text] [Related]
14. Significance of delayed graft function in cyclosporine-treated recipients of cadaver kidney transplants.
Barry JM; Shively N; Hubert B; Hefty T; Norman DJ; Bennett WM
Transplantation; 1988 Feb; 45(2):346-8. PubMed ID: 3278427
[TBL] [Abstract][Full Text] [Related]
15. Comparison of kidney transplant survival between patients treated with cyclosporine and those treated with azathioprine and antithymocyte globulin.
Cho SI; Bradley JW; Monaco AP; Tilney NL
Am J Surg; 1984 Apr; 147(4):518-23. PubMed ID: 6370008
[TBL] [Abstract][Full Text] [Related]
16. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
Najarian JS; Fryd DS; Strand M; Canafax DM; Ascher NL; Payne WD; Simmons RL; Sutherland DE
Ann Surg; 1985 Feb; 201(2):142-57. PubMed ID: 3882063
[TBL] [Abstract][Full Text] [Related]
17. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
18. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.
Boudreaux JP; McHugh L; Canafax DM; Ascher N; Sutherland DE; Payne W; Simmons RL; Najarian JS; Fryd DS
Transplantation; 1987 Sep; 44(3):376-81. PubMed ID: 3307061
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with cyclosporine and azathioprine at Brigham and Women's Hospital.
Milford EL; Kirkman RL; Tilney NL; Strom TB; Carpenter CB
Am J Kidney Dis; 1985 Jun; 5(6):313-7. PubMed ID: 3925762
[TBL] [Abstract][Full Text] [Related]
20. Is cyclosporine A-induced nephrotoxicity in recipients of renal allografts progressive?
Thiel G; Mihatsch M; Landmann J; Hermle M; Brunner FP; Harder F
Transplant Proc; 1985 Aug; 17(4 Suppl 1):169-78. PubMed ID: 3895657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
